Immunohistochemistry for Myc predicts survival in colorectal cancer

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Toon, Christopher W ^a,b   Chou, Angela ^a,c   Clarkson, Adele ^a,d   DeSilva, Keshani ^d   Houang, Michelle ^a,d   Chan, Joseph C Y ^a,e   Sioson, Loretta L ^a,d   Jankova, Lucy ^a,e   Gill, Anthony J ^a,d,e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Histopath Pathology   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MYC PROTEIN;

AGE; AGED; ARTICLE; BASE MISPAIRING; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR INVASION; ADOLESCENT; ADULT; COLORECTAL TUMOR; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MYC; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84895137216     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087456     Document Type: Article

References (19)

1. He T-C, Sparks AB, Rago C, Hermeking H, Zawel L, et al. (1998) Identification of c-MYC as a Target of the APC Pathway. Science 281: 1509-1512. (Pubitemid 28425575)
2. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, et al. (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359: 235-237.
3. Chan SK, Griffith OL, Tai IT, Jones SJM (2008) Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiology Biomarkers & Prevention 17: 543-552. (Pubitemid 351469203)
4. Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, et al. (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
5. Smith DR, Goh HS (1996) Overexpression of the c-myc proto-oncogene in colorectal carcinoma is associated with a reduced mortality that is abrogated by point mutation of the p53 tumor suppressor gene. Clin Cancer Res 2: 1049-1053. (Pubitemid 26198474)
6. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, et al. (2012) Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology 30: 3460-3467.
7. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, et al. (2012) Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology 30: 3452-3459.
8. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, et al. (2013) MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121: 4021-4031; quiz 4250.
9. Toon CW, Walsh MD, Chou A, Capper D, Clarkson A, et al. (2013) BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol 37: 1592-1602.
10. FT Bosman FC, RH Hruban, ND Theise (2010) WHO classification of Tumors of the DIgestive System 4th ed Lyon, France: IARC press; 2010.
11. Edge SB, Byrd DR, Compton CC (2009) AJCC Cancer Staging Manual, Springer, New York, NY, USA, 7th edition, 2009.
12. Toon CW, Chou A, Desilva K, Chan J, Patterson J, et al. (2013) BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Mod Pathol.
13. Erisman MD, Litwin S, Keidan RD, Comis RL, Astrin SM (1988) Noncorrelation of the Expression of the C-Myc-Oncogene in Colorectal-Carcinoma with Recurrence of Disease or Patient Survival. Cancer Research 48: 1350-1355. (Pubitemid 18075558)
14. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, et al. (2007) HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 60: 768-772. (Pubitemid 47056905)
15. Miller F, Heimann TM, Quish A, Pyo DJ, Szporn A, et al. (1992) ras and c-myc protein expression in colorectal carcinoma. Study of cancer-prone patients. Dis Colon Rectum 35: 430-435.
16. Nagai MA, Habr-Gama A, Oshima CT, Brentani MM (1992) Association of genetic alterations of c-myc, c-fos, and c-Ha-ras proto-oncogenes in colorectal tumors. Frequency and clinical significance. Dis Colon Rectum 35: 444-451.
17. Bhatavdekar JM, Patel DD, Ghosh N, Chikhlikar PR, Trivedi TI, et al. (1997) Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 40: 785-790. (Pubitemid 27295049)
18. Williams ARW, Piris J, Wyllie AH (1990) Immunohistochemical Demonstration of Altered Intracellular-Localization of the C-Myc Oncogene Product in Human Colorectal Neoplasms. Journal of Pathology 160: 287-293. (Pubitemid 20136754)
19. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, et al. (2013) Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 105: 1151-1156.